IRIS
BONATI, Antonio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.734
EU - Europa 1.481
AS - Asia 822
OC - Oceania 2
AF - Africa 1
SA - Sud America 1
Totale 4.041
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.686
CN - Cina 696
IE - Irlanda 312
SE - Svezia 274
FI - Finlandia 235
IT - Italia 218
UA - Ucraina 213
DE - Germania 170
TR - Turchia 101
CA - Canada 48
GB - Regno Unito 20
BE - Belgio 14
IN - India 10
AT - Austria 9
SG - Singapore 9
NL - Olanda 5
IR - Iran 4
ES - Italia 3
CZ - Repubblica Ceca 2
HK - Hong Kong 2
RO - Romania 2
AU - Australia 1
BR - Brasile 1
CH - Svizzera 1
EE - Estonia 1
FR - Francia 1
LU - Lussemburgo 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
Totale 4.041
Salva come PNG Salva come JPEG
Città #
Chandler 333
Jacksonville 320
Dublin 311
Beijing 188
Nanjing 113
Ann Arbor 105
Izmir 91
Dearborn 87
Parma 86
Ashburn 71
Princeton 71
San Mateo 71
Jinan 47
Wilmington 47
Toronto 46
Hebei 41
Shenyang 39
Des Moines 30
Nanchang 29
Kunming 27
Shanghai 26
Helsinki 24
Hefei 20
Düsseldorf 18
New York 18
Boardman 17
Woodbridge 17
Changsha 15
Tianjin 15
Brussels 14
Guangzhou 13
Falls Church 12
Zhengzhou 12
Fremont 11
Grafing 11
Kocaeli 10
Taizhou 10
Haikou 9
Jiaxing 9
Leawood 9
Los Angeles 9
Bologna 8
Fuzhou 8
Lanzhou 8
Seattle 8
Vienna 8
Hangzhou 7
Redmond 7
Trezzano Sul Naviglio 7
Borås 6
Chengdu 6
Houston 6
Taiyuan 6
Bremen 5
Ningbo 5
Redwood City 5
Verona 5
Langhirano 4
Mestre 4
Novara 4
Savignano Sul Rubicone 4
Auburn Hills 3
Chongqing 3
London 3
Modena 3
Mountain View 3
Piacenza 3
Pune 3
Reggio Nell'emilia 3
San Felice Sul Panaro 3
Xian 3
Amsterdam 2
Ardabil 2
Arzano 2
Cambridge 2
Fairfield 2
Focsani 2
Gurgaon 2
Madrid 2
Marghera 2
Miami 2
Monmouth Junction 2
Mumbai 2
Padova 2
Providence 2
Puxian 2
Reggio Emilia 2
Sala Baganza 2
Treviso 2
Abbiategrasso 1
Ahmedabad 1
Auckland 1
Augusta 1
Baotou 1
Bari 1
Brno 1
Changchun 1
Chicago 1
Clearwater 1
Crevillente 1
Totale 2.650
Salva come PNG Salva come JPEG
Nome #
Functional interplay between NIK and c-Abl kinases limits response to Aurora inhibitors in multiple myeloma 196
MEK-INHIBITORS/ARSENIC TRIOXIDE COMBINATION THERAPY AS A NOVEL TREATMENT OPTION FOR TYROSINE KINASE INHIBITORS-RESISTANT PH+-LEUKEMIA 109
Lung cancer in patients with chronic lymphocytic leukemia: does the HER-2 oncogene play a role? 81
Treatment with Arsenic Trioxide (ATO) and MEK1 inhibitor activates the p73-p53AIP1 apoptotic pathway in leukemia cells 78
Elevated telomerase activity, minimal telomere loss in cord blood long-term cultures with extensive stem cell replication 74
Selection of myeloid progenitors lacking BCR/ABL mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genistein. 72
Pan-aurora kinase inhibitor MK-0457 synergistically potentiates Apo2l/TRAIL cytotoxicity in Multiple Mieloma cells sensitive and resistant to bortezomib 70
Early proinflammatory activation of renal tubular cells by normal and pathologic IgG 67
Ph1-positive acute myelocytic leukemia with high TdT levels. 64
Acenaphthenequinone thiosemicarbazone and its transition metal complexes: synthesis, structure, and biological activity. 64
T cell receptor genes: a glance at normal and malignant hematopoiesis. 63
Biochemical, Immunological, and Molecular Markers of Hemopoietic Precursor Cells. 63
Expression and activation of SHC/MAP kinase pathway in primary acute myeloid leukemia blasts. 62
BCL2 oncogene protein expression in human hematopoietic precursors during fetal life. 62
Downmodulation of ERK protein kinase activity inhibits VEGF secretion by human myeloma cells and myeloma-induced angiogenesis 61
Terminal deoxynucleotidyl transferase (TdT) levels in hairy cell leukemia. 61
Human T-cell receptor alpha chain gene during ontogeny 60
Combined treatment with the MEK inhibitor PD0325901 and Arsenic Trioxide has potent anti-tumor activity in vivo against human multiple myeloma xenograft model. 60
Arsenic Trioxide (ATO) and MEK1 inhibition synergize to induce apoptosis in acute promyelocytic leukemia cells 60
T-cell receptor beta-chain gene rearrangement and expression during human thymic ontogenesis. 59
Espressione degli antigeni CD1a, CD1b, CD1c in timo umano a diverse eta' dello sviluppo. 59
The new tumor suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of pro-angiogenic molecules by myeloma cells and suppresses hypoxia inducible factor (HIF)-1{alpha} activity being involved in myeloma-induced angiogenesis. 59
Arsenic Trioxide in hematological malignancies: the new discovery of an ancient drug. 58
Su di un caso di sclerodermia associato ad aplasia midollare globale. 58
MDM2 inhibition synergistically enhances cytotoxicity of MEK1 inhibitor and Arsenic Trioxide (ATO) in AML blasts that retain a functional p53 pathway 57
MEK-ERK pathway is expressed but not activated in high proliferating, self-renewing cord blood hematopoietic progenitors 57
Synthesis, spectroscopic characterization and biological properties of new natural aldehydes thiosemicarbazones 57
Aurora and IKK kinases cooperatively interact to protect multiple myeloma cells from Apo2L/TRAIL 57
Synthesis, characterisation, X-ray structure and biological activity of three new 5-formyluracil thiosemicarbazone complexes 57
Emerging MEK inhibitors 56
Expression of TCR beta chain gene N-diversity is not an early event in human thymic ontogeny 56
Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia 56
Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. 54
Role of GSTP1-1 in mediating the effect of As2O3 in the Acute Promyelocytic Leukemia cell line NB4. 54
Terminal deoxynucleotidyl transferase: a nuclear marker of hemopoietic precursors. Biochemical, immunological and clinical aspects. 54
Detection of the common acute lymphoblastic leukaemia antigen (CALLA) on B cells from human fetal tissues. A multiple phenotypic characterization. 53
Effect of the protein tyrosine kinase inhibitor genistein on normal and leukaemic haemopoietic progenitor cells. 53
Expression of the T1 (CD5, p67) surface antigen in B-CLL and B-NHL and its correlation with other B-cell differentiation markers. 53
Emerging Raf inhibitors 52
Synthesis, structure, spectroscopic properties and biological activity of mixed diorganotin(IV) complexes containing pyridine-2-carbaldehyde thiosemicarbazonato and diphenyldithiophosphinato ligands. 52
The fine structure of HNK-1 (Leu7) positive cells. A study using an immunoperoxidase technique. 52
Downmodulation of ERK activity inhibits the proliferation and induces the apoptosis of primary acute myelogenous leukemia blasts 52
La linfoadenopatia angio-immunoblastica: Osservazioni cliniche, patologiche ed immunologiche su di un caso. 51
La mielofibrosi idiopatica asplenomegalica. Osservazioni cliniche e considerazioni su cinque casi. 50
Phenotype of the terminal transferase-positive cells in human foetal liver and bone-marrow: analysis with monoclonal antibodies. 50
Discordant expression of terminal transferase and T cell receptor beta chain in fetal and pediatric thymocytes. 49
p73 and p53 pathway in human breast cancers. 49
TCR beta chain expression during human thymic development. 49
MEK1 inhibition sensitizes primary acute myelogenous leukemia to arsenic trioxide-induced apoptosis 48
Valutazione dell'attivita proliferativa delle cellule emopoietiche nelle sindromi preleucemiche. 48
Hemopoiesis during human fetal life. Present knowledge and future prospects. 47
Terminal deoxynucleotidyl transferase in human fetal tissues. 47
Targeting the cancer initiating cell: the ultimate target for cancer therapy. 46
Terminal deoxynucleotidyl transferase-positive B cell precursors in fetal lymph nodes and extrahemopoietic tissues. 45
Philadelphia-positive chronic myelogenous leukemia with typical bcr/abl molecular features and atypical, prolonged survival. 45
Terminal deoxynucleotidyl transferase (TdT) in human foetuses. An immunofluorescent and biochemical study. 44
Medicina molecolare: nuovi strumenti per la conoscenza e la cura delle patologie dell'uomo. 43
Terminal deoxynucleotidyl transferase (TDT) expression correlates with the presence of N regions during human thymic ontogeny 43
Phorbol ester-induced PKC{epsilon} down-modulation sensitizes AML cells to TRAIL-induced apoptosis and cell differentiation. 43
Leu-7-positive cells with monocyte phenotype show different ultrastructural features in comparison to Leu-7-positive cells with T-cell phenotype. 43
Selective Expression and Constitutive Phosphorylation of SHC Proteins in the CD34+ Fraction of Chronic Myelogenous Leukemias. 41
The combination of MEK inhibitors and Arsenic Trioxide triggers in vitro and in vivo synergistic cytotoxicity in multiple myeloma through multiple signaling pathways 41
Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways 41
Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors. 41
Progression of a myelodysplastic syndrome to pre-B acute lymphoblastic leukaemia with unusual phenotype. 41
MEK1/2 regulate normal BCR and ABL1 tumor-suppressor functions to dictate ATO response in TKI-resistant Ph+ leukemia 38
The p53 family protein p73 provides new insights into cancer chemosensitivity and targeting. 37
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. 36
A micro-mechanically motivated model for the strength of heat-treated glass 36
Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. 34
Regulation of proliferation and cytokine expression of bone marrow fibroblasts: role of c-myb. 33
Combined treatment with the MEK inhibitor PD0325901 and Arsenic Trioxide has potent antitumor activity in NOD-SCID mice bearing advanced tumors of human multiple myeloma. 30
null 30
MEK-INHIBITORS/ARSENIC TRIOXIDE COMBINATION THERAPY AS A NOVEL TREATMENT OPTION FOR TYROSINE KINASE INHIBITORS-RESISTANT PH plus -LEUKEMIA 23
Calibration of the Statistical-Interference Factors for the Design of Tempered Structural Glass 18
Totale 4.062
Salva come PNG Salva come JPEG
Categoria #
all - tutte 12.736
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.736
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019130 0 0 0 0 0 0 0 0 0 0 112 18
2019/20201.123 150 206 73 10 79 75 105 12 77 230 28 78
2020/2021499 2 70 37 3 82 17 35 13 111 19 101 9
2021/2022382 5 10 0 14 12 16 63 72 20 34 18 118
2022/20231.178 139 124 94 87 106 123 5 69 379 14 30 8
2023/2024299 33 47 17 8 55 68 24 9 15 23 0 0
Totale 4.062